Exane Derivatives’s Zillow Z Stock Holding History

Exane Derivatives’s Portfolio Z Stock Details Z Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,316	Closed	-$213K	–	1033
2022 Q1	$213K	Buy	+4,316	New	+$232K	0.06%	315
2021 Q4	–	Sell	-3	Closed	-$264	–	1083
2021 Q3	$264	Sell	3 -496	-99%	-$50.2K	﹤0.01%	996
2021 Q2	$55K	Buy	+499	New	+$60.7K	0.01%	642

Other funds holding Z

CIA

Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFP

Independent Franchise Partners London, United Kingdom $15.2B AUM 1.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCMI

Technology Crossover Management IX Menlo Park, California $690M AUM 42.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCMV

Technology Crossover Management VIII Menlo Park, California $346M AUM 14.09% 1-Year Est. Return

Exane Derivatives's Z Position: Q2 2022 in Review

Exane Derivatives sold out of Zillow (Z) in Q2 2022, closing a stake of 4,316 shares — an estimated $213K sold.

Exane Derivatives first reported a position in Z in Q2 2021 and held it in 3 quarters. The position peaked at $213K in Q1 2022. 392 funds tracked by Wall St. Rank hold Z as of Q2 2022.

Exane Derivatives reported no remaining Zillow position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 4,316 Zillow shares in Q2 2022, an estimated $213K.
Exane Derivatives first reported a position in Zillow in Q2 2021 and held it in 3 quarters.
Exane Derivatives's Zillow position peaked at $213K in Q1 2022.
392 funds tracked by Wall St. Rank held Zillow as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.